Strategic Timing of AntiRetroviral Treatment (START): This is a large randomized international clinical trial comparing early antiretroviral treatment (ART) versus deferred ART in treatment naïve HIV positive persons to investigate the optimal time to begin ART.
The START study is being conducted at 229 clinics in 35 countries across the world. In April 2009 the first patient was enrolled into START, at that time the enrolment goal was to include 4000 participants. Since then there have been statistical adjustments to the protocol necessitating the need to enhance the total sample size to 4600 participants. CHIP coordinates 56 clinics, in 13 countries, participating in START across Europe:
Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, Germany, Luxembourg, Norway, Poland, Portugal, Spain and Sweden
For a complete list of participating countries and clinics go to the INSIGHT website